Healthcare services remains one of the most actively pursued sectors in private markets — and one of the most fragmented. Thousands of founder-owned clinics, labs, and specialty groups still sit outside any platform, in a market where demand is structurally underwritten by demographics. That combination, scarcity of scaled assets against durable demand, is exactly what a long-horizon owner wants.
The timing has improved, too. After a frothy 2024, healthcare-services M&A multiples have reset — clearing around 11.5x EV/EBITDA on a 2025 median, down from roughly 14.5x the year before. Entry discipline is rewarded again. The question for a family office is not whether to look at the sector, but where in it patient capital actually has an edge.
Where family capital has the edge
Family offices are not structurally advantaged everywhere. They are advantaged precisely where their character — patience, discretion, a multi-decade horizon, and a willingness to back management — is the deciding factor:
- Founder succession. A retiring founder choosing a steward, not just a price. Continuity and trust matter as much as the cheque — a setting where family capital routinely beats a sharper-elbowed sponsor.
- Cash-pay resilience. Sub-sectors with a strong private-pay component — ophthalmology, dermatology and aesthetics, fertility — trade at a premium for a reason: they are insulated from reimbursement risk and reward operational patience.
- Buy-and-build in fragmented niches. Diagnostics, home and behavioral care, veterinary — categories with abundant add-ons where a disciplined platform compounds over years, not quarters.
Where to be cautious
The same market punishes the undisciplined. Assets with heavy government-reimbursement exposure and thin margins — much of urgent and primary care — look cheap and stay cheap for structural reasons. Quality founder assets are scarce and competitive; over-paying at the top of a category erases the advantage of a good thesis. And in emerging lanes such as AI-enabled healthcare — a category compounding at extraordinary rates — the discipline is to underwrite real, recurring revenue and defensible data, not narrative.
A sketch of the map
The sub-sectors are not interchangeable. Dental platforms clear roughly 8–12x with more than a hundred sponsor-backed groups already active; ophthalmology, still only lightly penetrated by institutional capital, trades richer on cash-pay procedures; home health turns on reimbursement mix. A mandate that treats “healthcare services” as one thing will miss the point. The work is in the sub-sector, the situation, and the source.
The imperative
Move, but with discipline. The window — fragmentation, succession, and a multiple reset — is real and will not stay open indefinitely. The offices that capture it will be the ones with a sharp mandate, a sub-sector view rather than a sector slogan, and the patience to pass on the merely cheap in favour of the genuinely scarce.